<p>Edgewise Therapeutics, Inc.（纳斯达克代码：EWTX - 获取免费报告）获得了来自覆盖该公司的十一位分析师的共识推荐为 “适度买入”，Marketbeat.com 报道。一位研究分析师给予该股票卖出评级，三位给予持有评级，六位给予买入评级，还有一位给予强烈买入评级。在过去一年中，发布报告的分析师对该股票的平均一年目标价为 36.00 美元。</p>
<p>获取 <strong>Edgewise Therapeutics</strong> 的提醒：</p>
<ul>
<li>MarketBeat 周报 – 9/23 - 9/27</li>
</ul>
<p>几位股票研究分析师对 EWTX 股票发布了报告。加拿大皇家银行将 Edgewise Therapeutics 的目标价从 49.00 美元上调至 50.00 美元，并在 11 月 7 日的研究报告中给予该股票 “跑赢大盘” 评级。摩根大通将 Edgewise Therapeutics 的目标价从 33.00 美元上调至 34.00 美元，并在 11 月 14 日的研究报告中给予该公司 “增持” 评级。Wedbush 将 Edgewise Therapeutics 的目标价从 35.00 美元下调至 32.00 美元，并在 11 月 7 日的报告中为该公司设定了 “跑赢大盘” 评级。华尔街禅在周六的研究报告中将 Edgewise Therapeutics 的评级从 “持有” 下调至 “卖出”。最后，高盛集团在 9 月 25 日的研究报告中开始覆盖 Edgewise Therapeutics 的股票。他们给予该公司 “中性” 评级和 20.00 美元的目标价。</p>
<p><strong>查看我们最新的 Edgewise Therapeutics 股票报告</strong></p>
<h2>Edgewise Therapeutics 价格表现</h2>
<ul>
<li>分析师认为仍有时间投资 Edgewise，股价上涨 332%</li>
</ul>
<p>纳斯达克代码：EWTX 的股票在周五开盘价为 26.35 美元。该公司的 50 日移动平均价格为 21.30 美元，200 日移动平均价格为 16.77 美元。该公司的市值为 27.9 亿美元，市盈率为-16.68，贝塔值为 0.26。Edgewise Therapeutics 的一年低点为 10.60 美元，一年高点为 30.48 美元。</p>
<p>Edgewise Therapeutics（纳斯达克代码：EWTX - 获取免费报告）最近于 11 月 6 日发布了季度财报。该公司报告每股收益（EPS）为（0.39）美元，超出分析师共识预期的（0.40）美元，超出 0.01 美元。整体来看，股票研究分析师预计 Edgewise Therapeutics 本年度将发布-1.45 的每股收益。</p>
<h2>Edgewise Therapeutics 的内部活动</h2>
<ul>
<li>Edgewise Therapeutics 股价飙升 50%：背后的关键原因</li>
</ul>
<p>在相关消息中，董事 Jonathan C. Fox 于 11 月 11 日以每股 18.64 美元的平均成本购买了 10,700 股该公司的股票，总价值为 199,448.00 美元。购买后，该董事直接持有该公司 23,702 股股票，价值约为 441,805.28 美元。这笔交易代表了他们持股的 82.30% 的增加。该购买在向 SEC 提交的文件中披露，文件可在 SEC 网站上获取。此外，内部人士 Alan J. Russell 于 11 月 12 日的交易中出售了 100,000 股该股票，售价为每股 21.12 美元，总价值为 2,112,000.00 美元。出售后，该内部人士直接持有该公司 23,400 股股票，价值约为 494,208 美元。这笔交易代表了他们持股的 81.04% 的减少。有关此次出售的更多细节可在官方 SEC 披露中找到。23.20% 的股票由公司内部人士持有。</p>
<h2>机构投资者对 Edgewise Therapeutics 的看法</h2>
<p>大型投资者最近增加或减少了对该公司的持股。贝斯默集团在第三季度将其在 Edgewise Therapeutics 的持股增加了 1,170.3%。贝斯默集团现在拥有 2,350 股该公司的股票，价值 38,000 美元，此前在上个季度增持了 2,165 股。加拿大养老金计划投资委员会在第二季度购买了 Edgewise Therapeutics 的新头寸，价值约为 45,000 美元。琼斯金融公司在第一季度购买了 Edgewise Therapeutics 的新头寸，价值约为 47,000 美元。未来资产全球投资有限公司在第二季度将其在 Edgewise Therapeutics 的持股增加了 28.2%。未来资产全球投资有限公司现在拥有 4,062 股该公司的股票，价值 53,000 美元，此前在该期间增持了 894 股。最后，Allostery Investments LP 在第一季度购买了 Edgewise Therapeutics 的新股份，价值约为 66,000 美元。</p>
<h2>关于 Edgewise Therapeutics</h2>
<p>（获取免费报告）</p>
<p>Edgewise Therapeutics, Inc. 纳斯达克代码：EWTX 是一家临床阶段的生物制药公司，总部位于马萨诸塞州剑桥，专注于发现和开发用于治疗罕见疾病的精准药物。该公司利用其在小分子化学和离子通道生物学方面的专业知识，解决严重的未满足医疗需求，特别是在肾脏疾病和神经肌肉疾病领域。</p>
<p>Edgewise 的管线核心是 EWTX-101，这是一种新型的口服可用 TRPC5 抑制剂，TRPC5 是与肾病综合症（如局灶性节段性肾小管硬化症（FSGS））和其他蛋白尿性肾病相关的钙通道。</p>
<h2>阅读更多</h2>
<ul>
<li>我们更看好的五只股票比 Edgewise Therapeutics 更好</li>
<li>请勿删除，立即阅读</li>
<li>投资者提醒：微型 “3 美元人工智能奇迹股票” 即将爆发</li>
<li>资本利得税是否可以扣除任何费用？</li>
<li>你知道亚马逊计划在 1 月 1 日做什么吗？</li>
<li>巴菲特、盖茨和贝索斯悄然抛售股票——原因在这里</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVdUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVdUWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Edgewise Therapeutics 吗？</h2>
<p>在考虑 Edgewise Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Edgewise Therapeutics 并不在名单上。</p>
<p>虽然 Edgewise Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

EWTX

<p>Edgewise Therapeutics, Inc.（纳斯达克代码：EWTX）获得了十一位分析师的共识 “适度买入” 评级。平均一年期目标价为 36.00 美元。最近的分析师行动包括加拿大皇家银行、摩根大通和 Wedbush 对目标价的调整。内部交易活动包括显著的股票买入和卖出。机构投资者已调整在公司的持股比例。Edgewise Therapeutics 是一家专注于精准医疗的临床阶段生物制药公司</p>

<p>Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) has been assigned a consensus recommendation of &#34;Moderate Buy&#34; from the eleven analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $36.00.</p>
<div class="lb-trans"><p>Edgewise Therapeutics, Inc.（纳斯达克代码：EWTX - 获取免费报告）获得了来自覆盖该公司的十一位分析师的共识推荐为 “适度买入”，Marketbeat.com 报道。一位研究分析师给予该股票卖出评级，三位给予持有评级，六位给予买入评级，还有一位给予强烈买入评级。在过去一年中，发布报告的分析师对该股票的平均一年目标价为 36.00 美元。</p>
</div><p>Get <strong>Edgewise Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Edgewise Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>MarketBeat Week in Review – 9/23 - 9/27</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 周报 – 9/23 - 9/27</li>
</ul>
</div><p>Several equities research analysts have issued reports on EWTX shares. Royal Bank Of Canada lifted their price target on Edgewise Therapeutics from $49.00 to $50.00 and gave the stock an &#34;outperform&#34; rating in a research note on Friday, November 7th. JPMorgan Chase &amp; Co. increased their price target on shares of Edgewise Therapeutics from $33.00 to $34.00 and gave the company an &#34;overweight&#34; rating in a research report on Friday, November 14th. Wedbush lowered their price objective on shares of Edgewise Therapeutics from $35.00 to $32.00 and set an &#34;outperform&#34; rating for the company in a report on Friday, November 7th. Wall Street Zen cut shares of Edgewise Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday. Finally, The Goldman Sachs Group started coverage on shares of Edgewise Therapeutics in a research note on Thursday, September 25th. They issued a &#34;neutral&#34; rating and a $20.00 price target for the company.</p>
<div class="lb-trans"><p>几位股票研究分析师对 EWTX 股票发布了报告。加拿大皇家银行将 Edgewise Therapeutics 的目标价从 49.00 美元上调至 50.00 美元，并在 11 月 7 日的研究报告中给予该股票 “跑赢大盘” 评级。摩根大通将 Edgewise Therapeutics 的目标价从 33.00 美元上调至 34.00 美元，并在 11 月 14 日的研究报告中给予该公司 “增持” 评级。Wedbush 将 Edgewise Therapeutics 的目标价从 35.00 美元下调至 32.00 美元，并在 11 月 7 日的报告中为该公司设定了 “跑赢大盘” 评级。华尔街禅在周六的研究报告中将 Edgewise Therapeutics 的评级从 “持有” 下调至 “卖出”。最后，高盛集团在 9 月 25 日的研究报告中开始覆盖 Edgewise Therapeutics 的股票。他们给予该公司 “中性” 评级和 20.00 美元的目标价。</p>
</div><p><strong>View Our Latest Stock Report on Edgewise Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Edgewise Therapeutics 股票报告</strong></p>
</div><h2>Edgewise Therapeutics Price Performance</h2>
<div class="lb-trans"><h2>Edgewise Therapeutics 价格表现</h2>
</div><ul>
<li>Analysts Think There's Still Time to Get in on Edgewise, Up 332%</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师认为仍有时间投资 Edgewise，股价上涨 332%</li>
</ul>
</div><p>Shares of NASDAQ:EWTX opened at $26.35 on Friday. The company's fifty day moving average price is $21.30 and its 200-day moving average price is $16.77. The firm has a market capitalization of $2.79 billion, a price-to-earnings ratio of -16.68 and a beta of 0.26. Edgewise Therapeutics has a one year low of $10.60 and a one year high of $30.48.</p>
<div class="lb-trans"><p>纳斯达克代码：EWTX 的股票在周五开盘价为 26.35 美元。该公司的 50 日移动平均价格为 21.30 美元，200 日移动平均价格为 16.77 美元。该公司的市值为 27.9 亿美元，市盈率为-16.68，贝塔值为 0.26。Edgewise Therapeutics 的一年低点为 10.60 美元，一年高点为 30.48 美元。</p>
</div><p>Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.01. As a group, equities research analysts expect that Edgewise Therapeutics will post -1.45 EPS for the current year.</p>
<div class="lb-trans"><p>Edgewise Therapeutics（纳斯达克代码：EWTX - 获取免费报告）最近于 11 月 6 日发布了季度财报。该公司报告每股收益（EPS）为（0.39）美元，超出分析师共识预期的（0.40）美元，超出 0.01 美元。整体来看，股票研究分析师预计 Edgewise Therapeutics 本年度将发布-1.45 的每股收益。</p>
</div><h2>Insider Activity at Edgewise Therapeutics</h2>
<div class="lb-trans"><h2>Edgewise Therapeutics 的内部活动</h2>
</div><ul>
<li>Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge</li>
</ul>
<div class="lb-trans"><ul>
<li>Edgewise Therapeutics 股价飙升 50%：背后的关键原因</li>
</ul>
</div><p>In related news, Director Jonathan C. Fox purchased 10,700 shares of the firm's stock in a transaction on Tuesday, November 11th. The shares were acquired at an average cost of $18.64 per share, with a total value of $199,448.00. Following the purchase, the director directly owned 23,702 shares of the company's stock, valued at approximately $441,805.28. This trade represents a 82.30% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Alan J. Russell sold 100,000 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $21.12, for a total value of $2,112,000.00. Following the sale, the insider directly owned 23,400 shares of the company's stock, valued at approximately $494,208. This trade represents a 81.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 23.20% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事 Jonathan C. Fox 于 11 月 11 日以每股 18.64 美元的平均成本购买了 10,700 股该公司的股票，总价值为 199,448.00 美元。购买后，该董事直接持有该公司 23,702 股股票，价值约为 441,805.28 美元。这笔交易代表了他们持股的 82.30% 的增加。该购买在向 SEC 提交的文件中披露，文件可在 SEC 网站上获取。此外，内部人士 Alan J. Russell 于 11 月 12 日的交易中出售了 100,000 股该股票，售价为每股 21.12 美元，总价值为 2,112,000.00 美元。出售后，该内部人士直接持有该公司 23,400 股股票，价值约为 494,208 美元。这笔交易代表了他们持股的 81.04% 的减少。有关此次出售的更多细节可在官方 SEC 披露中找到。23.20% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Investors Weigh In On Edgewise Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Edgewise Therapeutics 的看法</h2>
</div><p>Large investors have recently added to or reduced their stakes in the company. Bessemer Group Inc. raised its stake in shares of Edgewise Therapeutics by 1,170.3% during the third quarter. Bessemer Group Inc. now owns 2,350 shares of the company's stock valued at $38,000 after acquiring an additional 2,165 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in Edgewise Therapeutics during the 2nd quarter valued at about $45,000. Jones Financial Companies Lllp bought a new position in Edgewise Therapeutics during the 1st quarter valued at approximately $47,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Edgewise Therapeutics by 28.2% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,062 shares of the company's stock worth $53,000 after buying an additional 894 shares during the period. Finally, Allostery Investments LP bought a new stake in shares of Edgewise Therapeutics in the 1st quarter worth approximately $66,000.</p>
<div class="lb-trans"><p>大型投资者最近增加或减少了对该公司的持股。贝斯默集团在第三季度将其在 Edgewise Therapeutics 的持股增加了 1,170.3%。贝斯默集团现在拥有 2,350 股该公司的股票，价值 38,000 美元，此前在上个季度增持了 2,165 股。加拿大养老金计划投资委员会在第二季度购买了 Edgewise Therapeutics 的新头寸，价值约为 45,000 美元。琼斯金融公司在第一季度购买了 Edgewise Therapeutics 的新头寸，价值约为 47,000 美元。未来资产全球投资有限公司在第二季度将其在 Edgewise Therapeutics 的持股增加了 28.2%。未来资产全球投资有限公司现在拥有 4,062 股该公司的股票，价值 53,000 美元，此前在该期间增持了 894 股。最后，Allostery Investments LP 在第一季度购买了 Edgewise Therapeutics 的新股份，价值约为 66,000 美元。</p>
</div><h2>About Edgewise Therapeutics</h2>
<div class="lb-trans"><h2>关于 Edgewise Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Edgewise Therapeutics, Inc NASDAQ: EWTX is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.</p>
<div class="lb-trans"><p>Edgewise Therapeutics, Inc. 纳斯达克代码：EWTX 是一家临床阶段的生物制药公司，总部位于马萨诸塞州剑桥，专注于发现和开发用于治疗罕见疾病的精准药物。该公司利用其在小分子化学和离子通道生物学方面的专业知识，解决严重的未满足医疗需求，特别是在肾脏疾病和神经肌肉疾病领域。</p>
</div><p>At the core of Edgewise's pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.</p>
<div class="lb-trans"><p>Edgewise 的管线核心是 EWTX-101，这是一种新型的口服可用 TRPC5 抑制剂，TRPC5 是与肾病综合症（如局灶性节段性肾小管硬化症（FSGS））和其他蛋白尿性肾病相关的钙通道。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>阅读更多</h2>
</div><ul>
<li>Five stocks we like better than Edgewise Therapeutics</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Do you know what Amazon is planning for January 1?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Edgewise Therapeutics 更好</li>
<li>请勿删除，立即阅读</li>
<li>投资者提醒：微型 “3 美元人工智能奇迹股票” 即将爆发</li>
<li>资本利得税是否可以扣除任何费用？</li>
<li>你知道亚马逊计划在 1 月 1 日做什么吗？</li>
<li>巴菲特、盖茨和贝索斯悄然抛售股票——原因在这里</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVdUWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=EWTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Edgewise Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Edgewise Therapeutics 吗？</h2>
</div><p>Before you consider Edgewise Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Edgewise Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edgewise Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Edgewise Therapeutics 并不在名单上。</p>
</div><p>While Edgewise Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Edgewise Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) 获得券商一致评级为 “适度买入”